2026-08-25 日報

🩺 醫藥健康每日摘要 - 第 210 期 (2026-08-25)

重點導讀

1. 經單株抗體與瑞德西韋治療之本迪布焦病毒疾病案例(A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir)

分析段落:此案例報告為本迪布焦病毒感染提供了首個成功的治療範例,結合了實驗性單株抗體雞尾酒療法 MBP134 與瑞德西韋。這項進展對於應對新興且高致死率的病毒性疾病具有重大意義,為未來相關療法的開發與評估奠定了基礎。

2. 成人與兒童暴露於本迪布焦伊波拉病毒後之單株抗體雞尾酒療法暴露後預防(Post-Exposure Prophylaxis with a monoclonal antibody cocktail Following Bundibugyo Ebolavirus Exposure in Adults and Children)

分析段落:這項研究顯示,單株抗體雞尾酒療法 MBP134 作為本迪布焦伊波拉病毒暴露後預防措施,在成人與兒童中表現出良好的耐受性,且無病毒感染證據。這對控制疫情傳播至關重要,為高風險暴露人群提供了潛在的預防工具,有望改變未來疫情管理策略。

3. 杜拜全市範圍內實施重症兒科病患快速全基因組定序計畫(Citywide implementation of a rapid whole-genome sequencing program for critically ill pediatric patients)

分析段落:杜拜醫療系統在新生兒與兒科加護病房推行全市快速全基因組定序計畫,結果顯示 53% 的患者臨床照護路徑發生了有意義的轉變。這項創新計畫凸顯了精準醫學在重症兒科領域的巨大潛力,能夠加速診斷並優化治療決策。

4. 莫德納與默沙東癌症疫苗的勝利內幕(Inside Moderna and Merck’s cancer vaccine triumph)

分析段落:莫德納與默沙東在癌症疫苗研發上取得的突破性進展,預示著免疫療法在腫瘤治療領域的新里程碑。這項合作的成功可能為多種癌症類型提供全新的治療選擇,大幅改善患者預後,並推動癌症治療進入個人化時代。

5. FDA 因安全疑慮再次暫停 Regenxbio 基因療法試驗(FDA pauses Regenxbio gene therapy trial again due to safety concerns)

分析段落:美國食品藥物管理局(FDA)再次暫停 Regenxbio 的基因療法試驗,凸顯了新興療法在臨床應用前嚴格安全性評估的重要性。此事件提醒業界需在創新與患者安全之間取得平衡,並可能影響未來基因療法開發的審批進程。

6. FDA 數位健康主管承諾將發布生成式 AI 監管指引(FDA digital health leader promises generative AI regulatory guidance is coming)

分析段落:隨著生成式人工智慧在醫療領域的應用日益增多,FDA 宣布將發布相關監管指引,這對確保 AI 醫療產品的安全性、有效性與可靠性至關重要。此舉將為 AI 醫療的創新與商業化提供明確的框架,同時保障患者權益。

7. 更新的肥胖症指引支持個人化照護並持續使用有效減重藥物(Updated obesity guideline supports personalized care and continued use of effective weight-loss medications)

分析段落:美國退伍軍人事務部和國防部發布的肥胖症管理指引,強調超越身體質量指數 (BMI) 的健康風險評估,並將生活型態干預作為基礎,彈性整合藥物治療(包括 GLP-1 療法)、內視鏡及手術選項。這項更新為肥胖症的綜合性、個人化治療提供了更全面的策略。

精細分類

Evidence (實證醫學)

Clinical (臨床研究與應用)

Guideline (醫療指引與政策)

Pharma (藥物研發與產業)

AI Medicine (AI 醫療應用)

Public Health (公共衛生)

  • 禽流感蔓延,您的後院餵食器可能使其惡化(Bird flu is spreading. Your backyard feeder could make it worse)
    Science Daily 報導警告,H5N1 禽流感在澳洲蔓延,後院鳥類餵食器可能成為病毒傳播的溫床。專家建議停止餵食野鳥,或採取嚴格的清潔措施和減少餵食量,以降低不同鳥類物種聚集導致病毒傳播的風險。
  • 原文連結:https://www.sciencedaily.com/releases/2026/08/260824065519.htm

  • 伊波拉病毒仍在中部非洲奪走生命,這些組織正努力挽救生命(Ebola Is Still Killing in Central Africa. These Groups Are Working To Save Lives.)
    KFF Health News 報導指出,伊波拉病毒仍在剛果民主共和國中部非洲地區造成死亡,當地衛生工作者正持續治療患者並培訓照護人員。這項工作對於控制有史以來第二致命的伊波拉疫情,挽救生命至關重要。

  • 原文連結:https://kffhealthnews.org/public-health/ebola-response-organizations-central-africa-democratic-republic-congo/

  • 豪大雨導致淹水頻傳!疾管署籲:當心 4 種傳染病上身,並以 5 項動作預防(豪大雨導致淹水頻傳!疾管署籲:當心 4 傳染病上身、以 5 動作預防)
    台灣疾管署提醒民眾,近日豪大雨後清理家園時,需警惕鉤端螺旋體病、類鼻疽、腸道傳染病以及登革熱等四種傳染病風險。建議採取五項預防措施,以避免接觸污水污泥,並防止病媒蚊孳生,保障個人健康。

  • 原文連結:https://heho.com.tw/archives/385960

  • 國際重要疫情(國際重要疫情)
    衛生福利部疾病管制署持續監測並發布全球各地的國際重要疫情資訊。這些即時更新對於台灣的邊境檢疫、疾病預防與控制策略的制定至關重要,有助於預防境外傳染病移入及國內社區傳播。

  • 原文連結:https://news.google.com/rss/articles/CBMiQkFVX3lxTFB0SXUtTzNTZmR6b1djMHJuNi1fYUNXV2FTRDFHNnJ2WFNnZTE5eVV3SEs1OU45ZXBBS0N0Y2Q1LVFFUQ?oc=5

  • 古柯鹼使用下降,但年輕人酒精濫用仍普遍(Cocaine use is down, but alcohol is still being abused by young adults)
    NPR 報導指出,儘管大學校園內的古柯鹼使用量有所下降,但年輕人酒精濫用問題依然普遍。這項研究提醒公眾與政策制定者,在關注非法藥物使用的同時,也應加強對酒精濫用危害的教育與預防措施。

  • 原文連結:https://www.npr.org/2026/08/24/nx-s1-5942987/cocaine-use-is-down-but-alcohol-is-still-being-abused-by-young-adults

Nutrition & Lifestyle (營養與生活型態)

其他未分類


English Daily Highlights

Today's medical and health news brings a mix of breakthroughs, regulatory updates, and public health concerns. A significant development comes from Nature Medicine, reporting the first successful treatment of a Bundibugyo virus patient using a monoclonal antibody cocktail (MBP134) combined with remdesivir. This case offers a crucial step forward for emerging viral disease therapies, complemented by another study highlighting MBP134's potential as a post-exposure prophylaxis for Bundibugyo ebolavirus in both adults and children, proving well-tolerated and effective in preventing disease onset.

In the realm of precision medicine, Dubai has successfully implemented a citywide rapid whole-genome sequencing program for critically ill pediatric patients, leading to clinically meaningful shifts in care for over half of the participants. This initiative demonstrates the transformative impact of genomics in acute care settings, paving the way for faster, more accurate diagnoses and personalized treatments.

Oncology saw exciting news with the "triumph" of Moderna and Merck's cancer vaccine, suggesting a new era for immunotherapy and personalized cancer treatment. However, the path of innovative therapies is not without hurdles, as the FDA again paused Regenxbio's gene therapy trial due to safety concerns. This reiterates the critical balance between therapeutic innovation and stringent safety oversight.

Looking ahead, the FDA's digital health leader promised upcoming regulatory guidance for generative AI in medicine. This move is essential for establishing clear frameworks for AI integration, ensuring both safety and efficacy as AI technologies become increasingly embedded in healthcare. Furthermore, updated obesity guidelines from the VA/DoD emphasize personalized care, comprehensive lifestyle interventions, and the flexible integration of effective weight-loss medications, including GLP-1 therapies, reflecting a more holistic approach to obesity management.

Beyond these highlights, the news covered various public health and lifestyle topics. Concerns were raised about backyard bird feeders exacerbating bird flu spread in Australia, and the persistent threat of Ebola in Central Africa. In nutrition, studies explored how common medications can long-term impact the gut microbiome and how gut bacteria can unlock hidden benefits from vegetables. Lifestyle news linked both too much and too little sleep to faster body aging and highlighted the muscle-preserving benefits of specific protein intake strategies for those over 45. Overall, today's report underscores a dynamic landscape in healthcare, driven by scientific advancements, evolving regulatory policies, and a growing focus on preventive and personalized medicine.